IntriCon Corporation (NASDAQ: IIN), a designer,
developer, manufacturer and distributor of miniature and
micro-miniature body-worn devices, today announced financial
results for its third quarter ended September 30, 2011.
For the 2011 third quarter, the company reported net sales of
$13.9 million, versus net sales of $14.7 million for the prior-year
period. IntriCon reported a net loss in the 2011 third quarter of
$489,000, or $0.09 per diluted share, compared to net income of
$243,000, or $0.04 per diluted share, for the prior-year third
quarter.
“Although economic softness has continued to adversely impact
our year-over-year results, we believe the long-term fundamentals
of the markets we serve remain strong,” said Mark S. Gorder,
president and chief executive officer of IntriCon. “In addition,
our strategic commitment to increasing R&D investment over the
last five years should better position IntriCon to meet the demand
for small and lightweight, advanced body-worn medical devices.
“Developing a larger portfolio of core technologies has allowed
us to pursue several high-potential initiatives for future growth.
In addition to the contract with hi HealthInnovations, a
UnitedHealth Group business, we have a recently FDA-approved
cardiac monitor that offers key patient benefits; and we continue
to incorporate our innovative PhysioLink® and nanoDSP® technology
into our product lines.”
Third-Quarter ResultsThird-quarter hearing health revenue
was flat with the prior-year third quarter, and down 7.3 percent
sequentially compared sequentially to the 2011 second quarter. The
overall hearing health industry remains soft, primarily driven by
low consumer confidence. Medical sales declined 8.9 percent
year-over-year, but increased 1.1 percent sequentially from the
2011 second quarter. IntriCon’s large medical customers continue to
face economic headwinds on several fronts including regulatory
delays and sluggish demand. Professional audio communications sales
were down 8.3 percent from the prior year third quarter, while
rising 8.7 percent sequentially.
Said Gorder, “Regarding hearing health, we believe continued
market acceptance of our innovative digital signal processing
circuits, such as our nanoDSP, Overtus™ DSP Amplifier, and complete
systems such as our APT™ and Lumen™ will drive future growth in
this business. In addition, the previously announced hi
HealthInnovations agreement holds tremendous potential.
“On the medical front, though sales remain sluggish due to
regulatory lead times and a few large customers working through
inventory levels, our large OEM customers are optimistic about
long-term prospects with IntriCon. Furthermore, we anticipate our
two wireless cardiac diagnostic monitoring devices—the Centauri,
which received FDA 510(k) approval in August and the Sirona, which
was submitted for FDA 510(k) approval in September—will provide
growth in 2012.”
As a percentage of total 2011 third-quarter revenue, IntriCon’s
medical business contributed 42 percent, with hearing health and
professional audio communications contributing 35 percent and 23
percent, respectively. This compares to 44 percent, 33 percent and
23 percent for medical, hearing health and professional audio
communications, respectively, in the 2010 third quarter.
Gross profits in the 2011 third quarter were 22.2 percent, down
from 25.9 percent in the prior-year period, mainly due to lower
sales volumes, costs related to establishing the company’s
Indonesian facility and ramp up associated with the hi
HealthInnovations agreement. The decrease in gross profits was
partially offset by the impact of various profit enhancement
programs.
Nine-Month ResultsFor the 2011 nine-month period,
IntriCon reported net sales of $41.6 million and a net loss of $1.1
million, or $0.19 per diluted share. This compares with 2010 net
sales of $44.2 million and net income of $530,000, or $0.10 per
diluted share.
Gross profits for the 2011 nine months were 22.4 percent, down
from 26.1 percent in the prior-year period, again primarily due to
the factors detailed above in the third-quarter gross profit
discussion.
IntriCon to Supply UnitedHealth Group Business with Hearing
AidsIn September 2011, IntriCon entered into an agreement to
become hi HealthInnovations’ supplier of hearing aids. hi
HealthInnovations has launched a suite of high-tech, lower-cost
hearing devices for the estimated 36 million Americans with hearing
loss. hi HealthInnovations will offer consumers technically
advanced hearing aids, including those based on IntriCon’s new APT
Open in-the-canal (ITC) hearing aid platform.
Said Gorder, “An estimated 75 percent of people who can benefit
from hearing devices do not use them, largely due to the high cost.
We’re working with hi HealthInnovations to deliver high-quality
hearing aids at affordable prices to an expanded population. As
previously noted, IntriCon expects to realize meaningful revenue
from this program beginning in the 2012 first quarter.”
As previously disclosed, IntriCon devoted considerable time and
resources during 2011 to securing the agreement and preparing for
the program’s launch. This had a significant adverse impact on the
company’s financial performance in 2011.
Key MilestonesDuring the third quarter, IntriCon received
510(k) marketing clearance from the FDA, for the Centauri
Ambulatory Patient ECG, its first-generation wireless cardiac
diagnostic monitoring (CDM) device. The Centauri combines event
recording with wireless transmission of patient data allowing
physicians to continuously monitor patient cardiac events
remotely.
The Centauri device provides diagnostic evaluation of patients
who experience transient symptoms that may suggest cardiac
arrhythmia. With continuous monitoring, automatic arrhythmia
detection and wireless transmission of the recorded cardiac
activity to a licensed physician for review, Centauri offers
flexibility and comfort not found in traditional devices. IntriCon
anticipates modest revenue contributions from this product in the
2012 first quarter.
PhysioLink, the company’s wireless technology, is currently
being incorporated into various product platforms. PhysioLink
enables audio and data streaming to ear-worn and body-worn
applications over distances of up to five meters. This advanced
wireless technology has applications across multiple
markets—including medical, hearing health and professional audio
communications.
The first product platform to incorporate the PhysioLink
wireless technology will be Sirona, the company’s second-generation
wireless CDM device. This small, rechargeable product platform can
be used as an event recorder, holter monitor or a wireless event
recorder. IntriCon submitted the Sirona for 510(k) approval with
the FDA in the third quarter.
During the third quarter, the company also amended its credit
facilities with The PrivateBank and Trust Company. Said Gorder,
“The extended terms and increased borrowing capacity enhance
IntriCon’s financial flexibility and strengthen the company in both
the short- and long-term. We’re using the facilities to fund
current growth opportunities, expand our low-cost manufacturing
footprint and meet anticipated working capital requirements.”
Concluded Gorder, “Although the third-quarter was impacted by
continued marketplace softness, we’re encouraged about our
prospects and future growth opportunities. We look forward to
supporting all of our customers by creating cost-effective,
high-quality and technically advanced body-worn devices based on
proprietary IntriCon technology.”
Conference Call TodayAs previously announced, the company
will hold an investment community conference call today, Tuesday,
November 8, 2011, beginning at 4:00 p.m. CT. Mark Gorder, president
and chief executive officer, and Scott Longval, chief financial
officer, will review third-quarter performance and discuss the
company’s strategies. To join the conference call, dial:
1-877-941-8631 (international 1-480-629-9772) and provide the
conference identification number 4483138 to the operator.
A replay of the conference call will be available one hour after
the call ends through 11:59 p.m. CT on Monday, November 14, 2011.
To access the replay, dial 1-800-406-7325 (international
1-303-590-3030) and enter access code: 4483138.
About IntriCon CorporationHeadquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops, manufactures and
distributes miniature and micro-miniature body-worn devices. The
company is focused on three key markets: medical, hearing health,
and professional audio communications. IntriCon has facilities in
the United States, Asia and Europe. The company’s common stock
trades under the symbol “IIN” on the NASDAQ Global Market. For more
information about IntriCon, visit www.intricon.com.
Forward-Looking StatementsStatements made in this release
and in IntriCon’s other public filings and releases that are not
historical facts or that include forward-looking terminology such
as “may”, “will”, “believe”, “anticipate”, “expect”, “should”,
“optimistic” or “continue” or the negative thereof or other
variations thereon are “forward-looking statements” within the
meaning of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, without limitation, statements
concerning prospects in the miniature body-worn device arena, new
products and their timing, strategic alliances, future growth and
expansion, expansion into new manufacturing facilities, market
fundamentals, future financial condition and performance, prospects
and the positioning of IntriCon to compete in chosen markets and
the Company’s planned investments in research and development.
These forward-looking statements may be affected by known and
unknown risks, uncertainties and other factors that are beyond
IntriCon’s control, and may cause IntriCon’s actual results,
performance or achievements to differ materially from the results,
performance and achievements expressed or implied in the
forward-looking statements. These risks, uncertainties and factors
include, without limitation, risks related to the current economic
crisis, the risk that IntriCon may not be able to achieve its
long-term strategy, weakening demand for products of the company
due to general economic conditions, risks related to the
manufacturing agreement with hi HealthInnovations, risks related to
the company’s strategic alliances and joint venture, possible
non-performance of developing the Centauri, Scenic, Overtus, APT,
Sirona, PhysioLink, Lumen, wireless glucose monitor and situational
listening device products and other technological products, the
volume and timing of orders received by the company, changes in the
mix of products sold, competitive pricing pressures, the cost and
availability of electronic components and commodities for the
company’s products, ability to create and market products in a
timely manner, competition by competitors with more resources than
the company, government regulation and review of products, foreign
currency risks arising from the company’s foreign operations,
ability to satisfy and maintain compliance with the covenants under
the company’s loan facility, the costs and risks associated with
research and development investments and other risks detailed from
time to time in the company’s filings with the Securities and
Exchange Commission, including the Annual Report on Form 10-K for
the year ended December 31, 2010. The company disclaims any intent
or obligation to publicly update or revise any forward-looking
statements, regardless of whether new information becomes
available, future developments occur or otherwise.
IntriCon Corporation Consolidated Condensed
Statements of Operations (in thousands, except per share data)
Three Months Ended Nine
Months Ended September 30, September 30, September
30, September 30, 2011 2010 2011 2010
(Unaudited) (Unaudited)
(Unaudited) (Unaudited) Sales, net
$ 13,873 $ 14,727 $ 41,584 $ 44,215 Cost of sales
10,789 10,912
32,261 32,693 Gross profit 3,084
3,815 9,323 11,522 Operating expenses: Sales and marketing
734 751 2,422 2,373 General and administrative 1,486 1,398 4,382
4,335 Research and development
1,326
1,231 3,600
3,455 Total operating expenses
3,546 3,380
10,404 10,163 Operating income
(loss) (462) 435 (1,081) 1,359 Interest expense (144) (158)
(431) (500) Equity in income (loss) of partnerships (12) 54 317 42
Other (expense) income
69
(57) 32 29
Income (loss) from continuing operations
before income taxes and discontinued operations
(549) 274 (1,163) 930 Income tax expense (benefit)
(60) 31 (90)
106 Income (loss) before discontinued
operations (489) 243 (1,073) 824
Loss from discontinued operations, net of
income taxes
-- -- -- (329)
Gain on sale of discontinued operations,
net of income taxes
-- --
-- 35 Net income (loss)
$ (489) $ 243
$ (1,073) $ 530
Basic income (loss) per share: Continuing operations $
(0.09) $ 0.04 $ (0.19) $ 0.15 Discontinued operations
$ 0.00 $ 0.00
$ 0.00 (0.05) Net
income (loss)
$ (0.09) $
0.04 $ (0.19) $
0.10 Diluted income (loss) per share:
Continuing operations $ (0.09) $ 0.04 $ (0.19) $ 0.15 Discontinued
operations
$ 0.00 $
0.00 $ 0.00
(0.05) Net income (loss)
$
(0.09) $ 0.04 $
(0.19) $ 0.10 Average
shares outstanding: Basic 5,600 5,485 5,576 5,477 Diluted 5,600
5,614 5,576 5,540
IntriCon Corporation
Consolidated Condensed Balance Sheets (in thousands, except per
share data) September 30,
2011 December 31, (Unaudited) 2010 Current assets: Cash $ 193 $ 281
Restricted cash 542 478 Accounts receivable, less allowance for
doubtful accounts of $223 at September 30, 2011 and $219 at
December 31, 2010 7,918 8,228 Inventories 9,713 8,331 Refundable
income taxes 205 -- Other current assets
1,011
446 Total current assets 19,582 17,764
Machinery and equipment 38,123 36,610
Less: Accumulated depreciation
31,700 30,184 Net machinery
and equipment 6,423 6,426 Goodwill 9,709 9,709 Investment in
partnerships 1,426 1,109 Other assets, net
1,071 1,259 Total assets
$ 38,211 $
36,267 Current liabilities: Checks written in
excess of cash $ 390 $ 409 Current maturities of long-term debt
2,727 2,095 Accounts payable 4,607 3,161 Accrued salaries, wages
and commissions 2,100 1,593 Deferred gain 110 110 Partnership
payable 260 260 Income taxes payable -- 24 Other accrued
liabilities
1,710 1,497
Total current liabilities 11,904 9,149 Long-term debt, less
current maturities 6,644 6,465 Other postretirement benefit
obligations 691 710 Long-term partnership payable 240 240 Deferred
income taxes 94 169 Accrued pension liabilities 436 464 Deferred
gain 413 495 Other long-term liabilities
123
4 Total liabilities 20,545 17,696
Commitments and contingencies Shareholders’ equity: Common
stock, $1.00 par value per share; 20,000 shares authorized; 6,136
and 6,073 shares issued; 5,620 and 5,557 shares outstanding at
September 30, 2011 and December 31, 2010, respectively
6,136
6,073
Additional paid-in capital 15,902 15,644 Accumulated deficit
(2,717) (1,644) Accumulated other comprehensive loss (390) (237)
Less: 516 common shares held in
treasury, at cost
(1,265) (1,265) Total
shareholders' equity
17,666
18,571 Total liabilities and shareholders’ equity
$ 38,211 $
36,267
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Apr 2024 to May 2024
Intricon (NASDAQ:IIN)
Historical Stock Chart
From May 2023 to May 2024